Scientists at Helmholtz Zentrum für Infektionsforschung GmbH and Medizinische Hochschule Hannover have divulged oxadiazole derivatives reported to be useful for the treatment of cytomegalovirus infections.

Researchers at Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have identified cyclohexane compounds acting as dopamine and/or 5-HT1A receptor ligands reported to be useful for the treatment of depression, schizophrenia, phobia, obsessive-compulsive disorder, cognitive disorders and bipolar disorder, among others.

Scientists at Bristol Myers Squibb Co. and Celgene Corp. have synthesized proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety coupled to a protein-targeting moiety through a linker.

Researchers at China Pharmaceutical University and Shanghai Institute of Materia Medica of the Chinese Academy of Sciences have disclosed short transient receptor potential channel 5 (TRPC5) and/or short transient receptor potential channel 4 (TRPC4) ligands reported to be useful for the treatment of cancer and more.

Vertex Pharmaceuticals Inc. has described orexin OX2 receptor agonists reported to be useful for the treatment of amyotrophic lateral sclerosis, obesity, hypertension, retinopathy, multiple sclerosis, narcolepsy, hypersomnia and Parkinson’s disease.

Celgene Corp. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to a MAP kinase-activated protein kinase 2 (MAPKAPK2; MK2)-targeting moiety via a linker.

Bioversys AG has identified rifabutin analogues reported to be useful for the treatment of bacterial and Mycobacterium abscessus infections.

Pinotbio Inc. has synthesized antibody-drug conjugates comprising an antibody covalently linked to DNA topoisomerase I inhibitors through a cleavable linker reported to be useful for the treatment of cancer.

Erasca Inc. has disclosed GTPase KRAS (G12D and G12V) mutant inhibitors reported to be useful for the treatment of cancer.

Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have described C-C chemokine receptor type 6 (CCR6) antagonists reported to be useful for the treatment of asthma, psoriasis, Crohn’s disease, ulcerative colitis, multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus.